Pembrolizumab
Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab
December 14, 2017Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab
November 10, 2017[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Pembrolizumab Improves Long-term Survival in Advanced Melanoma
June 03, 2016Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
Immunotherapy Drugs Shows Early Promise in Treating Tumors of Rare, Virus-linked Skin Cancer
May 11, 2016Half of 25 patients with Merkel cell carcinoma treated with pembrolizumab experienced significant tumor shrinkage that lasted almost 3 times longer than conventional chemotherapy, and some had no remaining disease after treatment.
Pembrolizumab Achieves Response and Increased Survival in Melanoma
May 11, 2016Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.
Sign Up for Free e-newsletters
ONA Articles
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- Myelofibrosis: From Diagnosis to Early Intervention
- FDA Approves HPV Vaccine for People Through Age 45
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population
- Eighth AJCC TNM Staging Equalizes Distribution, Improves Prognostics of Pancreatic Cancer Stages
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |